AstraZeneca/$AZN
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About AstraZeneca
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Ticker
$AZN
Sector
Health
Primary listing
Employees
94,300
Headquarters
Website
AstraZeneca Metrics
BasicAdvanced
$232B
14.19
$5.31
0.15
$1.52
2.73%
Price and volume
Market cap
$232B
Beta
0.15
52-week high
$87.01
52-week low
$61.24
Average daily volume
5M
Dividend rate
$1.52
Financial strength
Current ratio
0.863
Quick ratio
0.664
Long term debt to equity
57.992
Total debt to equity
73.508
Dividend payout ratio (TTM)
59.51%
Interest coverage (TTM)
10.77%
Profitability
EBITDA (TTM)
19,128
Gross margin (TTM)
82.26%
Net profit margin (TTM)
14.68%
Operating margin (TTM)
25.40%
Effective tax rate (TTM)
17.17%
Revenue per employee (TTM)
$600,000
Management effectiveness
Return on assets (TTM)
8.28%
Return on equity (TTM)
19.67%
Valuation
Price to earnings (TTM)
14.192
Price to revenue (TTM)
2.067
Price to book
3.84
Price to tangible book (TTM)
-11.91
Price to free cash flow (TTM)
14.028
Free cash flow yield (TTM)
7.13%
Free cash flow per share (TTM)
5.371
Dividend yield (TTM)
2.02%
Forward dividend yield
2.73%
Growth
Revenue change (TTM)
15.00%
Earnings per share change (TTM)
28.86%
3-year revenue growth (CAGR)
8.66%
10-year revenue growth (CAGR)
8.20%
3-year earnings per share growth (CAGR)
86.70%
10-year earnings per share growth (CAGR)
18.97%
3-year dividend per share growth (CAGR)
2.58%
10-year dividend per share growth (CAGR)
1.12%
What the Analysts think about AstraZeneca
Analyst ratings (Buy, Hold, Sell) for AstraZeneca stock.
AstraZeneca Financial Performance
Revenues and expenses
AstraZeneca Earnings Performance
Company profitability
AstraZeneca News
AllArticlesVideos
Ex-dividend day weighs heavily on the FTSE this week
Proactive Investors·6 days ago
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
WSJ·2 weeks ago
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
CNBC Television·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Sept8
AstraZeneca
Dividend·Payment
$0.515Per share
FAQs
What’s the current market cap for AstraZeneca stock?
AstraZeneca (AZN) has a market cap of $232B as of August 13, 2025.
What is the P/E ratio for AstraZeneca stock?
The price to earnings (P/E) ratio for AstraZeneca (AZN) stock is 14.19 as of August 13, 2025.
Does AstraZeneca stock pay dividends?
Yes, the AstraZeneca (AZN) stock pays dividends to shareholders. As of August 13, 2025, the dividend rate is $1.52 and the yield is 2.73%. AstraZeneca has a payout ratio of 59.51% on a trailing twelve-month basis.
When is the next AstraZeneca dividend payment date?
The next AstraZeneca (AZN) dividend payment is scheduled for September 08, 2025.
What is the beta indicator for AstraZeneca?
AstraZeneca (AZN) has a beta rating of 0.15. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.